PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Angew Chem Int Ed Engl. Author manuscript; available in PMC 2014 January 21.
Published in final edited form as:
PMCID: PMC3730258
NIHMSID: NIHMS496481

A Quantitative Analysis of the Fate of Au Nanocages after Uptake by U87-MG Tumor Cells under Both in vitro and in vivo Conditions**

Nanoparticles have been extensively used as carriers to deliver theranostic agents into tumors through the enhanced permeation and retention (EPR) effect,[1] and to regulate the release of a chemical or biological effector in response to environmental stimuli such as temperature or pH change.[2] In these cases, cell uptake of nanoparticles has been studied to maximize their delivery into the target cells. Cell uptake of nanoparticles has also been extensively investigated in an effort to understand their cytotoxicity and potential societal impacts.[3] Many reports have demonstrated that the uptake of nanoparticles by cells depends on their sizes,[4] shapes,[5] and surface properties,[6] among others.[7] However, it has not received much attention to monitor the fate of nanoparticles in cells or tissues as a funtion of time, which should be of great importance in understanding the delivery efficiency and toxicity of nanoparticles. In a recent in vitro study, it was demonstrated using a statistical method that nanoparticles in cells were distributed unequally when the cells divided.[8] However, the conclusion was drawn from an analysis of a large number of cells rather than by tracking the nanoparticles in individual cells during their division. In addtion, no such study has been reported for cells under in vivo conditions.

Herein we demonstrate two methods for monitoring and quantitatively analyzing the fate of Au nanocages (AuNCs) in U87-MG glioblastoma (brain tumor) cells under both in vitro and in vivo conditions. Figure 1a shows a schematic depicting the objective of this study, that is, to quantitatively measure the distributions of AuNCs in, as well as their clearance from the cells during proliferation of the cells. As a new class of nanoparticles with hollow interiors and porous walls, AuNCs have been extensively explored for biomedical applications including imaging, diagnostics, controlled release, and therapeutics,[9] due to their surface plasmon resonance (SPR) properties.[10] In the present work, we used their two-photon luminescence properties[10] and strong optical absorption[11] to track and quantify the numbers of AuNCs in the target cells or a tumor.

Figure 1
a) A schematic illustration of the major objective of this study: to quantitatively analyze the distributions of AuNCs in U87-MG brain tumor cells during their proliferation in vitro and in vivo. b) A typical TEM image of the AuNCs used for our experiments. ...

We used AuNCs with an outer edge length of ca. 50 nm for our study (Fig. 1b). They were prepared according to our previously published protocol.[12] Their surfaces were then functionalized with cyclic Arg-Gly-Asp-D-Tyr-Lys, or c(RGDyK), a peptide capable of specifically targeting the integrin receptors on U87-MG cells (Fig. 1c).[13]

We first quantified the cellular uptake of c(RGDyK)-covered AuNCs by incubating them at various particle concentrations with U87-MG cells at 37 °C for 24 h. The average number of AuNCs taken up by an individual cell was then determined using a UV-vis spectroscopic method (see Fig. S1 in the Supporting Information).[14] As shown in Figure 1d, the number of AuNCs taken up per cell monotonically increased when the particle concentration was increased.

We then used two-photon microscopy (TPM) to examine the fate of the uptaken AuNCs in vitro by calculating the number of AuNCs in each cell from the photoluminescence intensity. In this case, an incubation time of 24 h was used to ensure that each cell would contain ca. 4.0 × 103 AuNCs. The cells were harvested by trypsin treatment and re-seeded in a culture plate at a density of ca. 20 cells per plate. The seeded cells, referred to as mother cells, were then imaged individually using TPM and the photoluminescence intensity from each cell was recorded and integrated. Since the doubling time for the U87-MG cells is approximately 48 h, we were able to observe the divided cells (i.e., daughter cells) after the same sample had been incubated for 2 days.

Figure 2a shows a typical TPM image of a U87-MG mother cell at the time of seeding and Figure 2b shows a pair of daughter cells derived from this mother cell 2 days post seeding. A total of 14 mother cells and their 28 corresponding daughter cells were monitored and their images are collected in Figure S2. It is clear that all the mother cells divided into two daughter cells within a period of 2 days. Although some pairs of daughter cells showed different degrees of stretching and thus different areas, we assume that they should have equal volumes because this is usually the case when mammalian cells divide. By comparing with the calibration curve shown in Figure 2c, the photoluminescence intensity from each cell was used to determine the number of AuNCs in the cell. Figure 2d compares the average numbers of AuNCs per cell for the 14 mother cells and their corresponding 28 daughter cells after division. It is worth noting that the daughter cells did not equally share the uptaken AuNCs (per volume) during the division of a mother cell (p=0.02). When we added up the numbers of AuNCs in all the daughter cells, the total was reduced by ca. 20 ± 8% relative to what was contained in their mother cells, suggesting that some of the AuNCs were cleared by the cells during the 2-day period of culture. The drop in Au content was further confirmed by analyzing the culture medium with inductively coupled mass spectrometry (ICP-MS). During the 2-day period of culture, ca. 8% of the AuNCs re-entered into the culture medium. The drop in the number of AuNCs per cell could be attributed to the exocytosis and/or desorption of AuNCs bound to the surface of the cells.

Figure 2
a, b) Superimposed two-photon and phase contrast images showing (a) a U87-MG mother cell and (b) its two daughter cells after 2 days of culture. The photoluminescence from the cyclic RGD-labeled AuNCs is shown in green. c) A calibration curve for the ...

We also monitored the c(RGDyK)-covered AuNCs in vivo using photoacoustic microscopy (PAM).[15] In this case, U87-MG cells bearing ca. 4.0 × 103 AuNCs per cell were harvested by trypsin treatment and re-suspended in a culture medium at a density of ca. 1 × 107 cells/mL. Next, 20 μL of the cell suspension was injected subcutaneously at the dorsal side of a nude mouse. Immediately after the injection, a PAM image of the cells in the nude mouse was acquired at an excitation wavelength of 770 nm, and the growth of the tumor was monitored by PAM imaging every 2 days until 6 days post injection. Figure 3 shows time-lapse photographs of the tumor (indicated by the arrow) in the mouse (Fig. 3ad) and the corresponding PAM maximum amplitude projection (MAP) images (Fig. 3eh, X-Y plane; Fig. 3il, X-Z plane; and Movie S1–4, 3D reconstructions; the signals from blood vessels were removed). The photoacoustic amplitude for the tumor area gradually decreased over time. Meanwhile, the thickness of the tumor (in the depth direction from the surface of skin) greatly increased, leading to the growth of tumor volume from ca. 1.26 mm3 to ca. 6.28 mm3 in 6 days. By treating the explanted tumors (in parallel control groups) with a combination of collagenase and trypsin, it was found that the number of tumor cells increased from ca. 2.0 × 105 to ca. 9.4 × 105 in 6 days.

Figure 3
a–d) Time-lapse photographs showing a tumor growing on the dorsal side of a nude mouse after subcutaneous injection of U87-MG cells containing the AuNCs. The tumor was non-invasively monitored using PAM up to 6 days post injection. e–l) ...

Based on the PAM images shown in Figure 3, we estimated the total number of AuNCs (Ntotal) within the tumor at each time point. In this case, we first obtained a calibration curve for in vivo use (Fig. 4a and Fig. S3). The photoacoustic amplitude averaged from the entire region of the proliferating tumor at each time point (Fig. 4b) was then converted to the number of AuNCs per cell based on the calibration curve. Multiplying the number of nanocages per cell by the number of tumor cells at each time point, we were able to estimate Ntotal in the tumor. As shown in Figure 4c, Ntotal decreased by ca. 12 ± 10% in 6 days, implying that the AuNCs were likely cleared from the cells and then carried away from the tumor site through blood flow. However, the decrease in Ntotal was not linearly correlated with time. Instead, Ntotal decreased rapidly in the first 2 days and then stabilized up to day 6.

Figure 4
a) Calibration curve for photoacoustic amplitude (PA) as a function of the number of AuNCs in U87-MG cells. Four sets of cells bearing different numbers of nanocages per cell were injected subcutaneously into the dorsal side of a nude mouse, and the photoacoustic ...

The present study provides an important, quantitative understanding of the distribution and clearance of AuNCs in U87-MG tumor cells both in vitro and in vivo. A plot of Ntotal as a function of time indicates that some of the uptaken AuNCs were cleared by the cells over time (Table 1). We determined the percentage of reduction in Ntotal by ICP-MS, TPM, and PAM. In general, the cells or tumor lost ca. 10–20% of the initial AuNCs over a period of 2–6 days both in vitro and in vivo. This data suggests that the clearance of AuNCs from the tumor cells did not vary significantly whether the cells were grown in vitro or in vivo for the period of time tested (4–6 days).

Table 1
Percentages of AuNCs cleared from the cells.a

In addition, the standard deviation of the number of AuNCs per cell in the entire cell population over time represented the distribution of the AuNCs in the cells or the tumor during their proliferation. Table 2 shows the percentage standard deviation relative to the number of AuNCs per cell obtained from UV-vis, TPM, and PAM. On day 0, the percentages obtained from the three techniques agreed with each other reasonably well (with variations in the range of 18–20%). The percentages increased over time both in vitro and in vivo. The increasing value of standard deviation implies that the number of AuNCs in the cells or the tumor became increasingly different among the cells during their proliferation. In other words, this result suggests that the cells likely did not share the AuNCs equally when they divided.

Table 2
Percentages of standard deviation (STD) for the average number of AuNCs per cell in the entire cell population.a

In conclusion, we have quantitatively analyzed the fate of target-specific AuNCs in a brain tumor cell line both in vitro and in vivo. As a novel class of nanoparticles with hollow interiors and porous walls, AuNCs are finding wide use in drug delivery and cancer therapeutics.[9] The tunable scattering and absorption peaks of AuNCs in the near-infrared region also make them excellent contrast agents for a number of optical imaging modalities. All of these applications require a quantitative understanding of their fates once they have been delivered into cells. In the present study, by using TPM and PAM, it was found that the cells did not share the AuNCs equally during their division. We believe that a comparison of the fates of the AuNCs between in vitro and in vivo cases could also provide useful information on the biological activities of tumor cells under different physiological conditions. The present work is important to future studies involving nanoparticles for biomedicine and nanotoxicology, where it is critical to know the delivery efficiency and/or the fate of nanoparticles in the cells during prolonged periods of proliferation.

Supplementary Material

Supporting Information

Footnotes

**This work was supported in part by a grant from NIH (R01 CA138527) and startup funds from Washington University in St. Louis (to Y. X.), and NIH Grants R01 EB000712, R01 EB008085, R01 CA134539, U54 CA136398, and 5P60 DK02057933 (to L. V. W.). Part of the research was done at the Alafi Neuroimaging Laboratory, the Hope Center for Neurological Disorders (NIH Neuroscience Blueprint Center Core Grant P30 NS057105).

Supporting information for this article, including procedures for the synthesis of AuNCs, surface modification, and cell culture, two photon microscopy, and photoacoustic imaging, is available on the WWW under http://dx.doi.org/.

References

[1] a) Ghosh P, Han G, De M, Kim CK, Rotello VM. Adv Drug Deliv Rev. 2008;60:1307–1315. [PubMed]b) Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. J Control Rel. 2000;65:271–284. [PubMed]
[2] a) Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, Torchilin VP. Bioconj Chem. 2006;17:943–949. [PMC free article] [PubMed]b) Rosler A, Vandermeulen GWM, Klok HA. Adv Drug Deliv Rev. 2001;53:95–108. [PubMed]
[3] a) Nel A, Xia T, Madler L, Li N. Science. 2006;311:622–627. [PubMed]b) Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. Toxicol Sci. 2007;95:300–312. [PubMed]c) Lison D, Thomassen LCJ, Rabolli V, Gonzalez L, Napierska D, Seo JW, Kirsch-Volders M, Hoet P, Kirschhock CEA, Martens JA. Toxicol Sci. 2008;104:155–162. [PubMed]
[4] a) Jiang W, Kim BYS, Rutka JT, Chan WCW. Nat Nanotechnol. 2008;3:145–150. [PubMed]b) Alivisatos AP, Gu W, Larabell C. Annu Rev Biomed Eng. 2005;7:55–76. [PubMed]c) Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Biochem J. 2004;377:159–169. [PubMed]d) Panyam J, Labhasetwar V. Adv Drug Deliv Rev. 2003;55:329–347. [PubMed]e) Prabha S, Zhou WZ, Panyam J, Labhasetwar V. Int J Pharm. 2002;244:105–115. [PubMed]
[5] a) Cho EC, Au L, Zhang Q, Xia Y. Small. 2010;6:517–522. [PubMed]b) Chithrani BD, Chan WCW. Nano Lett. 2007;7:1542–1550. [PubMed]
[6] a) Verma A, Stellacci F. Small. 2010;6:12–21. [PubMed]b) Verma A, Uzun O, Hu Y, Hu Y, Han HS, Watson N, Chen S, Irvine DJ, Stellacci F. Nat Mater. 2008;7:588–595. [PubMed]c) Leroueil PR, Hong S, Mecke A, Baker JR, Jr, Orr BG, Holl MMB. Acc Chem Res. 2007;40:335–342. [PubMed]d) Cho EC, Xie J, Wurm PA, Xia Y. Nano Lett. 2009;9:1080–1084. [PubMed]e) Zorko M, Langel U. Adv Drug Deliv Rev. 2005;57:529–545. [PubMed]f) Sudimack J, Lee RJ. Adv Drug Deliv Rev. 2000;41:147–162. [PubMed]
[7] a) Alexandre A, Chan WCW. ACS Nano. 2011;5:5478–5489. [PubMed]b) Lin J, Zhang H, Chen Z, Zheng Y. ACS Nano. 2010;4:5421–5429. [PubMed]c) Chakravarthy KV, Bonoiu AC, Davis WG, Ranjan P, Ding H, Hu R, Bowzard JB, Bergey EJ, Katz JM, Knight PR, Sambhara S, Prasad PN. Proc Natl Acad Sci. 2010;107:10172–10177. [PubMed]d) Hutter E, Boridy S, Labrecque S, Lalancette-Hebert M, Kriz J, Winnik FM, Maysinger D. ACS Nano. 2010;4:2595–2606. [PubMed]
[8] Summers HD, Rees P, Holton MD, Brown MR, Chappell SC, Smith PJ, Errington RJ. Nat Nanotechnol. 2011;6:170–174. [PubMed]
[9] Xia Y, Li W, Cobley CM, Chen J, Xia X, Zhang Q, Yang M, Cho EC, Brown PK. Acc Chem Res. 2011;44:914–924. [PMC free article] [PubMed]
[10] Au L, Zhang Q, Cobley CM, Gidding M, Schwartz AG, Chen J, Xia Y. ACS Nano. 2010;4:35–42. [PMC free article] [PubMed]
[11] a) Chen J, Wiley B, Li ZY, Campbell D, Saeki F, Cang H, Au L, Lee J, Li X, Xia Y. Adv Mater. 2005;17:2255–2261.b) Cho EC, Kim C, Zou F, Cobley CM, Song KH, Chen J, Li ZY, Wang LV, Xia Y. J Phy Chem C. 2009;113:9023–9028. [PMC free article] [PubMed]
[12] Skrabalak SE, Au L, Li X, Xia Y. Nat Protoc. 2007;2:2182–2190. [PubMed]
[13] Chen X, Park R, Tohme M, AHS. Bading JR, Conti PS. Bioconjugate Chem. 2004;15:41–49. [PubMed]
[14] a) Cho EC, Liu Y, Xia Y. Angew Chem Int Ed. 2010;49:1976–1980. [PMC free article] [PubMed]b) Cho EC, Zhang Q, Xia Y. Nat Nanotechnol. 2011;6:385–391. [PubMed]
[15] a) Zhang HF, Maslov K, Stoica G, Wang LV. Nat Biotechnol. 2006;24:848–851. [PubMed]b) Kim C, Cho EC, Chen J, Song KH, Au L, Favazza C, Zhang Q, Cobley CM, Gao F, Xia Y, Wang LV. ACS Nano. 2010;4:4559–4564. [PubMed]